WaveMan
WaveMan · Company
IMRX · Immuneering Corp
> Search tickers & screens ⌘K
LIVE
← All companies

IMRX Immuneering (IMRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001790340
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
73
13F, latest reported quarter

What the filings say about IMRX

Insiders, 180 days
+$36.0K net bought
2 buyers

Immuneering insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Immuneering Corp insiders bought a net $36.0K of stock across 74 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Zeskind Benjamin J.
PRESIDENT AND CEO
BUY
2026-06-24 SECtraded 2026-06-23
2,400
$10.9K
-18.1%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jul 2, 2025.
  • +40.0% median (+48.7% mean) 90-day return after 7 previous buys.
  • The trade is 0.1% of the 2,315,252 shares held after it.
  • 1 other insider bought within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Zeskind Benjamin J. bought about $10.9K of IMRX on Jun 23, 2026; 1 other insider bought within 30 days and 73 funds added in the latest 13F quarter.
Hall Brett Matthew
CHIEF SCIENTIFIC OFFICER
BUY
2026-06-16 SECtraded 2026-06-15
6,035
$25.0K
-15.9%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jan 15, 2026.
  • +40.0% median (+78.6% mean) 90-day return after 7 previous buys.
  • The trade is 1.6% of the 382,531 shares held after it.
  • 1 other insider bought within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought about $25.0K of IMRX on Jun 15, 2026; 1 other insider bought within 30 days and 73 funds added in the latest 13F quarter.
Brakewood Harold Eugene
Chief Business Officer
BUY
2026-01-21 SECtraded 2026-01-16
5,250
$25.0K
-30.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 20, 2025.
  • +103.6% median (+103.6% mean) 90-day return after 2 previous buys.
  • The trade is 47.5% of the 11,050 shares held after it.
  • 4 other insiders bought within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Brakewood Harold Eugene bought about $25.0K of IMRX on Jan 16, 2026; 4 other insiders bought within 30 days and 73 funds added in the latest 13F quarter.
Schall Thomas J.
Director
BUY
2026-01-20 SECtraded 2026-01-15
21,645
$101.1K
-23.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 27, 2025.
  • +126.6% median (+137.9% mean) 90-day return after 3 previous buys.
  • The trade is 29.0% of the 74,530 shares held after it.
  • 4 other insiders bought within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schall Thomas J. bought about $101.1K of IMRX on Jan 15, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 73 funds added in the latest 13F quarter.
Hall Brett Matthew
CHIEF SCIENTIFIC OFFICER
BUY
2026-01-16 SECtraded 2026-01-15
2,298
$10.5K
-22.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 23, 2025.
  • +51.4% median (+87.7% mean) 90-day return after 6 previous buys.
  • The trade is 0.6% of the 376,496 shares held after it.
  • 4 other insiders bought within 30 days.
  • 73 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought about $10.5K of IMRX on Jan 15, 2026; 4 other insiders bought within 30 days and 73 funds added in the latest 13F quarter.
74 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 69 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$36.0K over 180 days
more than 71% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
73 funds bought in last quarter
more than 57% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
33.2% of the float short (float per yahoo 2026-10-27) · 20.4 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IMRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-34.1%12M
-39%-10%+19%+48%2025-102025-122026-022026-042026-062026-082026-10 2026-01-15 · Schall Thomas J. bought $101.1K2026-01-12 · Feinberg Peter bought $87.0K2026-06-15 · Hall Brett Matthew bought $25.0K2026-01-16 · Brakewood Harold Eugene bought $25.0K2026-06-23 · Zeskind Benjamin J. bought $10.9K2026-01-13 · Neufeld Leah R bought $10.9K2026-01-15 · Hall Brett Matthew bought $10.5K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IMRX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
9,704,610 sh
$48.4M
BlackRock, Inc.
4,374,020 sh
$21.8M
Sanofi
2,708,559 sh
$13.5M
VANGUARD CAPITAL MANAGEMENT LLC
2,286,434 sh
$11.4M
GEODE CAPITAL MANAGEMENT, LLC
1,370,750 sh
$6.8M

Congress trades in IMRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IMRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IMRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$249.5K position · as of 2026-06-30
0.3%
Ultra-Small Company Market Fund
$248.7K position · as of 2026-06-30
0.2%
Select Biotechnology Portfolio
$6.3M position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$899.9K position · as of 2026-06-30
0.1%
T. Rowe Price New Horizons Fund, Inc.
$4.5M position · as of 2026-06-30
0.0%
Guardian Large Cap Fundamental Growth VIP Fund
$48.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
1 active
2
Multi-phase
1 active
What changed recently
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
2026-10-21 · Completion moved 2026-06 → 2027-06
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $36.0K bought by insiders over 180 days, 73 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IMRX financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2023-01-01 to 2023-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$57.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-52.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-47.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-56.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-59.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$0$317.0K
Gross profitn/an/a$0$158.8K
Operating income-$59.4M-$64.1M-$58.4M-$51.7M
Net income-$56.0M-$61.0M-$53.5M-$50.5M
EPS (diluted)-1.27-2.04-1.88-1.91
Operating cash flow-$45.3M-$55.0M-$49.0M-$44.1M
Cash$128.6M$36.1M$59.4M$72.6M
SEC XBRL, fiscal years, as known on 2026-10-28

IMRX Stock Sonar score 5/7 axes

Find similar shapesCompare

IMRX ranks highest on insider conviction (76th percentile) and institutional and government (57th), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
48
Inputs
  • Return on equity-52.1% · 53 pct, sector of 545
  • Return on assets-47.3% · 46 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-56.0% · 45 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$36K · 70 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
57
Inputs
  • Funds adding, latest quarter73 · 57 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+33.2% · 3 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.9% · 72 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IMRX filings, in plain words

Are Immuneering insiders buying or selling IMRX?

In the 180 days to 2026-10-28, Immuneering insiders were net buyers, a net $36.0K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Immuneering insiders were net buyers of IMRX, a net $36.0K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies